Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This move strengthens the Board as Clinigen advances its ...

The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.

Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

Enhanced Genomics has appointed Dr Dietrich Stephan as Chair of the Board of Directors. In this role, Dietrich will guide ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Closed Loop Medicine (CLM) has appointed Kate Woolland as Chief Executive Officer. Previously serving as Chief Operating ...

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...

Why supporting representative trial participation matters ...

CLEO Systems is also part of the NHS Pathfinder pilot programme with around 200 community pharmacies in England, further ...

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T cells within the tumour microenvironment, with the goal of amplifying ...

eXmoor Pharma and Signadori Bio have entered into a partnership aimed at advancing a gene-modified monocyte-derived macrophage cell therapy programme for solid tumours.